1. Home
  2. SNGX vs POLA Comparison

SNGX vs POLA Comparison

Compare SNGX & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.39

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Logo Polar Power Inc.

POLA

Polar Power Inc.

HOLD

Current Price

$1.76

Market Cap

6.0M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNGX
POLA
Founded
1987
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
6.0M
IPO Year
2006
2016

Fundamental Metrics

Financial Performance
Metric
SNGX
POLA
Price
$0.39
$1.76
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
291.5K
1.8M
Earning Date
05-08-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
57.03
N/A
EPS
N/A
N/A
Revenue
$119,371.00
$24,801,141.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.14
52 Week Low
$0.28
$1.31
52 Week High
$6.23
$5.70

Technical Indicators

Market Signals
Indicator
SNGX
POLA
Relative Strength Index (RSI) 47.98 56.81
Support Level $0.37 $1.51
Resistance Level $0.41 $1.81
Average True Range (ATR) 0.02 0.20
MACD 0.01 0.04
Stochastic Oscillator 73.39 41.84

Price Performance

Historical Comparison
SNGX
POLA

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About POLA Polar Power Inc.

Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Other Asia Pacific, Europe and Middle East, United Kingdom, and South Africa.

Share on Social Networks: